Literature DB >> 21454061

Conditions associated with severe carbon monoxide diffusion coefficient reduction.

Lize Kiakouama1, Vincent Cottin, Jean-Charles Glerant, Jean-Yves Bayle, Jean-François Mornex, Jean-François Cordier.   

Abstract

OBJECTIVE: To identify conditions associated with severe carbon monoxide transfer coefficient reduction (Kco < 40% of predicted values). PATIENTS AND METHODS: We retrospectively reviewed pulmonary function tests, such as Kco measurement, in consecutive patients evaluated in the physiology unit of a University hospital over a 6-year period. Patients were included if they had at least 1 measure of severe Kco reduction, with further detailed pulmonary function tests, clinical data, and diagnostic procedures conducted within 6 months.
RESULTS: 5576 patients underwent 9061 Kco measurements. 195 patients (3.5%) with Kco < 40% were investigated (156 males; mean age 62 ± 12 years). Mean Kco was 29 ± 9% of predicted values. The main conditions associated with severe Kco reduction were: emphysema (46%); interstitial lung disease (28%); combined pulmonary fibrosis and emphysema (16%); and pre-capillary pulmonary hypertension (8%). Systolic pulmonary artery pressure was ≥ 35 mmHg at echocardiography in 88% of patients. Right heart catheterization performed in 97 patients showed pre-capillary pulmonary hypertension in 86 of 195 patients (44%). Pulmonary hypertension was the most frequent condition associated with Kco severe reduction. Pulmonary hypertension was present in 29%, 53%, and 48% of patients with chronic obstructive pulmonary disease, interstitial lung disease, and combined pulmonary fibrosis and emphysema, respectively, and was disproportionate to the parenchymal lung disease (mean pulmonary artery pressure > 35 mmHg) in 63% of cases.
CONCLUSION: Severe Kco reduction is frequently related to pulmonary hypertension, especially when associated with emphysema and/or interstitial lung disease. Systematic echocardiography is thus warranted in any patient with severe Kco diminution.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21454061     DOI: 10.1016/j.rmed.2011.03.004

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  7 in total

Review 1.  Combined pulmonary fibrosis and emphysema (CPFE): an entity different from emphysema or pulmonary fibrosis alone.

Authors:  Huijin Lin; Shanping Jiang
Journal:  J Thorac Dis       Date:  2015-04       Impact factor: 2.895

Review 2.  Combined pulmonary fibrosis and emphysema syndrome: a review.

Authors:  Matthew D Jankowich; Sharon I S Rounds
Journal:  Chest       Date:  2012-01       Impact factor: 9.410

Review 3.  Group 3 Pulmonary Hypertension: From Bench to Bedside.

Authors:  Navneet Singh; Peter Dorfmüller; Oksana A Shlobin; Corey E Ventetuolo
Journal:  Circ Res       Date:  2022-04-28       Impact factor: 23.213

4.  Centrilobular emphysema combined with pulmonary fibrosis results in improved survival: a response.

Authors:  Vincent Cottin; Jean-François Cordier; Athol U Wells
Journal:  Fibrogenesis Tissue Repair       Date:  2011-07-25

5.  Pulmonary function impairment in patients with combined pulmonary fibrosis and emphysema with and without airflow obstruction.

Authors:  Yoshiaki Kitaguchi; Keisaku Fujimoto; Masayuki Hanaoka; Takayuki Honda; Junichi Hotta; Jiro Hirayama
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2014-07-29

6.  HRCT diagnosis of combined pulmonary fibrosis and emphysema in a patient of chronic obstructive pulmonary disease with pulmonary hypertension and clinical or radiograph suspicion of pulmonary fibrosis.

Authors:  Kataveeranahally Shekar Manjunath; Hirennappa Udnur
Journal:  BJR Case Rep       Date:  2016-11-02

7.  Effect of combined pulmonary fibrosis and emphysema on patients with connective tissue diseases and systemic sclerosis: a systematic review and meta-analysis.

Authors:  Bon San Koo; Kyu Yong Park; Hyun Jung Lee; Hyun Jung Kim; Hyeong Sik Ahn; Shin-Young Yim; Jae-Bum Jun
Journal:  Arthritis Res Ther       Date:  2021-04-06       Impact factor: 5.156

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.